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Abstract
Patients with autosomal dominant hypercholesterolemia (ADH) have a high
risk of developing cardiovascular disease that can be effectively treated using
statin drugs. Molecular diagnosis and family cascade screening is recommended
for early identification of individuals at risk, but up to 40% of families have no
mutation detected in known genes. This study combined linkage analysis and
exome sequencing to identify a novel variant in exon 3 of APOB (Arg50Trp).
Mass spectrometry established that low-density lipoprotein (LDL) containing
Arg50Trp APOB accumulates in the circulation of affected individuals, suggest-
ing defective hepatic uptake. Previously reported mutations in APOB causing
ADH have been located in exon 26. This is the first report of a mutation out-
side this region causing this phenotype, therefore, more extensive screening
of this large and highly polymorphic gene may be necessary in ADH families.
This is now feasible due to the high capacity of recently available sequencing
platforms.
Introduction
Autosomal dominant hypercholesterolemia (ADH) is a
relatively common autosomal dominant condition with a
prevalence of around 1 in 500 in the United Kingdom
population. ADH is associated with a greatly increased risk
of early onset cardiovascular disease; this risk is reduced
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by treatment with statin drugs (Neil et al. 2008). Clinical
diagnosis in the United Kingdom is guided by the Simon
Broome criteria based on cholesterol levels, presence of
tendon xanthomata, family history of premature cardio-
vascular disease and hypercholesterolemia, and molecular
testing to assign a diagnosis of definite or possible familial
hypercholesterolemia (FH) (Scientific Steering Committee
on behalf of the Simon Broome Register Group 1991).
Most cases of ADH are caused by mutations in the LDLR
gene, which encodes the low-density lipoprotein receptor
(LDLR) protein, which binds LDL particles at the cell
membrane and internalizes them for hepatic processing
and excretion. Rare autosomal dominant gain-of-function
mutations in PCSK9 (proprotein convertase subtilin-kex-
in-type 9) can cause a severe form of ADH. A pathogenic
mutation at residue 3527 in APOB (apolipoprotein B), the
specific ligand for binding of LDL to the LDLR, has been
known for over two decades to cause the autosomal domi-
nant condition familial defective apolipoprotein-B100
(FDB), a form of ADH (Soria et al. 1989), and a second
variant in this region, Arg3558Cys, has also been associ-
ated with hypercholesterolemia (Pullinger et al. 1995). In
a recent study, exome sequencing identified two further
variants in this region of APOB, each in one unrelated
ADH family (Motazacker et al. 2012). In individuals with
these mutations, LDL with the defective APOB has
reduced affinity for the LDLR, impairing LDL clearance
and causing hypercholesterolemia with a phenotype simi-
lar to that caused by LDLR mutations. APOB is a large
and highly polymorphic gene, complicating identification
of pathogenic variants. Screening of this gene in ADH
families has therefore mainly focussed on the region of
exon 26 around residue 3527.
The detection rate for pathogenic mutations in ADH
varies depending on the diagnostic criteria and molecular
techniques used, from 50% to 60% with stringent clinical
criteria and full gene screening, to around 20–30% in
standard lipid clinic populations (Taylor et al. 2010). A
comprehensive study sequencing known genes in a
cohort of children with suspected ADH in the Nether-
lands detected mutations in 95% of cases, suggesting that
a minimum of 1 in 20 FH families has a causative muta-
tion which is yet to be identified (van der Graaf et al.
2011).
Exome sequencing has become established as an effec-
tive tool for gene identification in Mendelian disease, par-
ticularly in combination with linkage analysis, as it
provides a comprehensive list of candidate variants in
linked genetic loci of any size, without any prior assump-
tion of disease mechanism (Gilissen et al. 2012). We
present here results of linkage and exome sequencing in
a family with ADH, providing further evidence of the
efficacy of this approach in this common treatable disease.
Methods
Family members were recruited under ethics approval
REC 2002/6451. Sequencing of LDLR, APOB exon 26,
and PCSK9 in I:2 identified no causative mutations.
Libraries were prepared with the Agilent (Santa Clara,
CA) SureSelect All Exon 50 Mb kit followed by Illumina
(San Diego, CA) 100 bp paired-end sequencing (see Sup-
plementary methods online). Read mapping used BWA
(Li and Durbin 2009), and variant calling used GATK
(McKenna et al. 2010). Analysis of APOB used the RefSeq
sequence NM_000384.2. Genome-wide genotyping was
carried out using Illumina Human CytoSNP-12 v2.1
beadchips; the data were analyzed with Merlin linkage
analysis software (see Supplementary methods online)
(Abecasis et al. 2002). LDL from three affected family
members (I:2, II:2, and II:5), one unaffected family mem-
ber (I:1), and an unrelated control was purified from
plasma by single ultracentrifugation (Chung et al. 1980).
Wild-type and mutant peptides were quantitated by mass
spectrometry (see Supplementary methods online).
Results
The pedigree is shown in Figure 1, with lipid profiles given
in Table 1. Linkage analysis was carried out in all individu-
als in generations I, II, and III shown in Figure 1, assigning
affected status to the four individuals with high cholesterol
and tendon xanthomata (I:2, II:1, II:2, and II:5), and
unknown clinical status for II:4 with high cholesterol but
no xanthomata. Two additional family members in whom
DNA but no phenotypic data were available were included
in the genotyping to assist with haplotype identification.
Overall, 20 linkage regions were identified with maximum
log of odds (LOD) score 1.2, covering a total of 245 Mb,
approximately 8% of the genome.
Exome sequencing generated an average of 176 million
reads for each of seven family members (I:1, I:2, II:1, II:2,
II:3, II:4, and II:5 in Fig. 1), of which 83% mapped
within targeted regions or the 200 bp flanking these
regions. Average coverage within the targeted regions was
64-fold (range 55- to 87-fold), and 86% of targeted bases
were covered at minimum 10-fold. A total of 54,745 vari-
ants were identified in the seven individuals. Capillary
sequencing of a subset of coding variants confirmed cor-
rect calls of 146 genotypes at 21 loci with no false posi-
tives. From the exome sequence data 4932 variants were
identified within loci identified by linkage analysis, of
which 1275 were nonsynonymous, essential splice site,
truncating or frameshift variants. Of these, 41 segregated
with the disease (i.e., were heterozygous only in the
affected individuals), and 12 were novel or had minor
allele frequency (MAF) less than 0.01 in dbSNP (Sayers
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et al. 2012), 1000 genomes project database (The 1000
Genomes Project Consortium 2010), and the NHLBI exo-
mes project (Exome Variant Server, NHLBI Exome
Sequencing Project [ESP], Seattle, WA [http://evs.gs.
washington.edu/EVS/]). The 12 rare or novel segregating
variants identified within linked loci are shown in Table
S1 together with a summary of known functions of these
genes. Eleven of the genes have known functions that are
not related to lipid metabolism; the 12th was the missense
variant p.Arg50Trp (c.148C>T) in APOB (NM_000384.2),
which is a likely candidate for disease causation. Capillary
sequencing confirmed the presence of this variant in the
Table 1. Lipid profiles of family members prior to initiation of lipid-lowering therapy.
Individual Age at measurement BMI Total cholesterol (mmol/L) Triglycerides (mmol/L) HDL (mmol/L) LDL (mmol/L)
I11 71 24 5.4
I2 69 26 11.5 2.1 0.9 9.5
II1 50 24 8.3 0.9 1.9 6
II2 46 24 8.4 0.9 1.9 6.1
II3 57 26 5.6 1 1.3 3.8
II4 43 28 7.3 1.2 1.4 5.4
II5 49 27 8.3 1 1.9 5.9
III1 22 21 3.9 2.2 1.2 1.7
Affected individuals are shaded in gray. BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
1A full lipid profile was not available prior to lipid-lowering therapy, which was initiated for secondary prevention of coronary vascular disease in
this individual some years after his myocardial infarction.
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Figure 1. Pedigree and clinical information. Individuals with black symbols have the full phenotype of hypercholesterolemia together with tendon
xanthomata; the individual with a gray symbol represents a phenocopy with high cholesterol but no xanthomata. Haplotypes within the APOB
locus are shown for individuals with sequence data; Arg50Trp is highlighted in black in the haplotype tables. Chol, total cholesterol measurement
prior to initiation of lipid-lowering treatment (mmol/L); tendon X, tendon xanthomata; MI, myocardial infarction; CVA, cerebrovascular accident.
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individuals with hypercholesterolemia and tendon xantho-
mata (I:2, II:1, II:2, and II:5) and its absence in all other
available family members (I:1, II:3, II:4, and III:1). APOB
Arg50Trp was absent from dbSNP, NHLBI ESP, and 1000
genomes project data. In silico tools were used to predict
its effect on protein structure and function: Polyphen-2
predicted Arg50Trp to be probably damaging (score 1.0)
(Adzhubei et al. 2010), the SIFT prediction was deleteri-
ous (score 0) (Kumar et al. 2009), and the Condel predic-
tion was also of deleterious effect (score 0.762)
(Gonzalez-Perez and Lopez-Bigas 2011). This arginine
residue is conserved in 27 of 29 mammals and in seven
of eight of the lower species with 1:1 orthologues of this
region of APOB identified by the Ensembl database. Over-
all, these in silico predictions suggest a functional effect of
this variant. Haplotypes within the APOB locus are shown
in Figure 1.
APOB encodes the protein component of the LDL par-
ticle, forming a shell around a core of lipid molecules.
LDL is cleared from the circulation by interaction with
the LDLR, and this interaction has been shown to be dis-
rupted by the FDB-causing mutations Arg3527Gln,
Arg3527Trp, and Arg3558Cys (Gaffney et al. 1995; Pullin-
ger et al. 1995). One of the methods used to study the
effects of these FDB mutations is determination of the
mutant:wild-type protein ratio in the circulation. Defec-
tive interaction between LDL and the LDLR results in
reduced clearance of mutant LDL, while wild-type LDL is
cleared normally from the circulation. Wild-type LDL
therefore represents less than 50% of circulating LDL.
For the Arg3527Gln mutation, the mutant:wild-type ratio
has been found to be around 70:30, while for the
Arg3558Cys mutation the ratio averaged 59:41 using
dynamic laser light scattering (Pullinger et al. 1995). We
determined the abundance of mutant and wild-type LDL
in individuals with Arg50Trp and control samples using
mass spectrometry (Fig. 2). The mutant peptide was pres-
ent at concentrations 2.5- to 3.5-fold higher than wild-
type peptide in all three affected individuals, giving a
ratio of mutant:wild-type peptide between 72:28 and
78:22. The technique used to generate these ratios was
different from previously reported techniques and there-
fore the ratios may not be directly comparable, but these
results suggest that mutant APOB accumulates in the cir-
culation as with other hypercholesterolemic APOB muta-
tions, most likely due to defective hepatic uptake and
clearance.
Discussion
In recent years, exome sequencing of large numbers of
individuals has revealed many thousands of coding vari-
ants in every genome, and distinguishing pathogenic vari-
ants among these has proved a significant challenge.
However, combining exome sequencing with linkage data
in this family reduced the number of candidate variants
by 91%, and applying knowledge of the inheritance pat-
tern of the disease allowed further reduction by focusing
on segregating variants. Increasing availability of databases
of rare coding variation improves detection of novel vari-
ants, although the databases may contain genuine patho-
genic variants in some phenotypes, and must therefore be
used with caution when excluding variants from further
analysis. This is particularly likely with conditions such as
hypercholesterolemia, as “control” individuals from these
databases may not have had their lipid profile analyzed.
Interpreting the potential functionality of variants identi-
fied by exome sequencing is frequently complex, especially
where candidate variants are found within genes about
which little is known. In this family, the most significant
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Figure 2. Mass spectrometry of APOB peptides. Following digestion
with GluC, wild-type peptide (NVSLVCPKDATRFKHLRKYTYNYE) was
present in all samples, and mutated peptide (NVSLVCPKDA
TRFKHLWKYTYNYE) was present only in affected individuals II:5, I:2,
and II:2 and not in unaffected family members or the unrelated
control. The abundance of the two peptides was quantified from the
peak intensities using synthetic peptides in three replicate experiments
(A). In all patient samples, the mutant peptide was present at 2.5- to
3.5-fold greater concentration than wild-type peptide (B).
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variant was within APOB, a gene which has been exten-
sively studied in the context of hyperlipidemia, allowing
ex vivo functional studies to be designed which were able
to establish a difference between the wild-type and
mutant proteins, lending strong support to this variant as
the causative mutation in this family. A recent report of
exome sequencing in ADH patients demonstrated retro-
spectively that individual I:2 from this family was
included in another research cohort; APOB Arg50Trp was
detected in this individual in this project, but no segrega-
tion or functional data was generated, and the mutation
was presented as a variant of unknown significance
(Futema et al. 2012).
Previous studies have used dynamic laser light scatter-
ing to establish the proportions of wild-type and variant
APOB. This technique relies on the variant of interest
being present on the same haplotype as a common poly-
morphism, which is detected by binding of the MB19
monoclonal antibody. For higher frequency mutations
such as Arg3527Gln and Arg3558Cys this was an effective
technique, but it is not applicable to rare variants in
APOB because many families will be wild-type for the
MB19 polymorphism, as with the family presented here.
Mass spectrometry was therefore used for quantification
of wild-type and mutant peptide in this family, to show
allele imbalance for the circulating levels of APOB. This
technique should also be adaptable to study LDL obtained
from families with other rare APOB variants, in order to
establish the range of mutations in APOB which cause
hyperlipidemia. Previous studies have used mass spec-
trometry to quantify APOB in human samples (Agger
et al. 2010), but this study represents the first report of
the use of mass spectrometry to determine the ratios of
wild-type and mutant proteins. Other studies have used
trypsin to digest APOB, but trypsin cleaves at arginine
residues and therefore a single peptide encompassing the
Arg50Trp variant could not have been generated using
the standard digestion approach. Digestion with GluC
was used instead which generated two peptides from LDL
of affected individuals with identical length, but differing
in one amino acid (NVSLVCPKDATRFKHLRKYTYNYE
and NVSLVCPKDATRFKHLWKYTYNYE).
In order to determine accurately the ratio of mutant to
wild-type peptide, internal standards with known concen-
trations were used (ThermoFisher Scientific, Waltham,
MA). The standard peptides had identical sequences to
the peptides of interest, but contained a heavy labeled
lysine causing a mass shift of 8 Da. The standard peptides
were spiked into the digests and used to calculate the
abundance of the endogenous peptides and determine
the ratio of mutant to wild-type peptide. This allowed the
ratios to be determined accurately and with high preci-
sion, with coefficients of variance (CVs) for the individual
peptide abundances between 3% and 10% and CVs for
the mutant:wild-type ratio between 6% and 12%. The
small CVs indicate that using standard peptides provided
satisfactory correction for technical variation resulting
from the slight difference in the amino acid composition
of the mutant and wild-type peptides, such as differential
ionization or recovery.
Exon 3 of the APOB gene is 116 base pairs in length
and contains little reported variation: one synonymous
SNP (rs12720850) at residue 43, and two rare variants,
Tyr56His (rs150496608) and Ala73Asp, both of which
have been found in a single individual in the 6500 exome
sequences in the NHLBI Exome Variant Server. The syn-
onymous SNP rs12720850 is the only variant in exon 3
found in the 1000 genomes project database. This lack of
nonsynonymous variation suggests an important func-
tional role for this region of the protein. The APOB pro-
tein is structurally organized into five alternating b-sheet
and a-helical domains. Mutations currently known to
cause ADH are located in exon 26 in the b2 domain,
which interacts directly with LDLR (Prassl and Laggner
2009). Exon 3 forms a small part of the first domain
(ba1), which is a compact globular structure. This
domain is predicted to direct hepatic assembly of lipopro-
tein molecules, as well as to affect the interaction of LDL
particles with lipases and macrophage scavenger receptors.
Detailed information on the specific role of exon 3 in
these processes is not available, but the high level of
amino acid conservation in this exon, together with the
predicted damaging effect of Arg50Trp on protein func-
tion, and its absence in control datasets, suggest that this
exon and in particular this nucleotide substitution are
functionally important and the likely cause of hypercho-
lesterolemia in this family. Two mechanisms could
account for this. First, conformational changes in this
highly conserved region of APOB could affect the interac-
tion of LDL with LDLR and thereby increase levels of cir-
culating LDL. Second, the mutant APOB protein could be
protected from degradation prior to LDL particle assem-
bly, stimulating the release of increased numbers of
mutant very low density lipoprotein particles (VLDL) into
the circulation, with the downstream effect of increasing
LDL concentration. Triglyceride (and therefore VLDL)
levels in the affected members of this family were within
the normal range despite elevated LDL (Table 1). This
suggests that reduced hepatic clearance of LDL due to
defective interaction with LDLR is more likely than
increased production of mutant lipoprotein particles, but
further investigation of the exact mechanism in this fam-
ily is beyond the scope of this article.
Haplotypes around the APOB locus are shown in Fig-
ure 1. The background haplotype on which the Arg50Trp
mutation lies is identical in I:1 and I:2; it is possible that
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this has occurred due to the distant consanguinity in the
family, which would indicate that the Arg50Trp mutation
arose within the three generations above generation I in
this pedigree. This would be consistent with rare variants
of large effect being of recent origin in evolutionary
terms. However, within 1000 genomes data, 17.4% of
individuals of British origin (GBR) shared this back-
ground haplotype, and the presence of this haplotype in
I:1 and I:2 may therefore be unrelated to the consanguin-
ity in the family.
This study represents the first report of a mutation in
APOB outside exon 26 causing ADH, suggesting that a
wider range of APOB domains can influence the interac-
tion between APOB and LDLR than was previously con-
sidered. In order to determine which regions of this large
and highly polymorphic gene can be mutated to cause
ADH, sequencing of all 29 coding exons of APOB will be
required in large patient cohorts using the increased
sequencing capacity of high-throughput platforms. Fol-
low-up of rare and novel variants in families using the
mass spectrometry protocol presented here will enable
distinction of variants causing ADH from nonfunctional
polymorphisms. This is likely to increase the number of
families with a detectable molecular cause for ADH,
enabling cascade screening in these families and poten-
tially increasing the understanding of the interactions
between the LDL particle and the LDLR.
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